Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

11 COVID-19 therapies you need to know

By Brian Buntz | December 22, 2020

5. Olumiant, a rheumatoid arthritis drug, shows COVID-19 promise

Winning an EUA for COVID-19 patients, Olumiant is primarily indicated for adults with moderately to severely active rheumatoid arthritis. Image courtesy of Eli Lilly.

Developer: Eli Lilly (NYSE:LLY)

Description: Olumiant (baricitinib), an anti-inflammatory medication, effectively reduces lung inflammation in COVID-19 patients when administered early after infection, according to a peer-reviewed study. FDA approved the Janus kinase inhibitor in 2018 for patients with moderate to severe rheumatoid arthritis.

The EUA for the product describes its use in “adult and pediatric patients 2 years and older with severe COVID-19 in combination with remdesivir.”

Development status: The product won emergency use in Nov. 2020. Lilly initially filed for an EUA to use Olumiant as a monotherapy but revised its application to use the drug with remdesivir.

Next>>


Filed Under: clinical trials, Drug Discovery, Infectious Disease
Tagged With: AstraZeneca plc, BioNTech, clinical trials, coronavirus, covid-19, COVID-19 vaccine, COVID-19 vaccine trial, Donald Trump, Eli Lilly & Co., FDA, GlaxoSmithKline, GSK, Janssen Pharmaceuticals, Johnson & Johnson, Merck, Moderna, National Institutes of Health, Pfizer, Regeneron
 
Pages: 1 2 3 4 5 6 7 8 9 10 11 12

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Lab facility
Massachusetts is competing for ARPA-H biomedical research center
Blockchain
Startup vies to get blockchain adoption in pharma off the ground
Black Diamond Therapeutics
Black Diamond analysis highlights 22 new oncogenic HER2 driver mutations
NIH National Institutes of Health
NIH licenses COVID-19 research technologies to WHO initiative

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50